B
BioVersys
Privately held Swiss biopharmaceutical company
About BioVersys
BioVersys is a Swiss pharmaceutical company based in Basel, specializing in the research and development of small molecules targeting antimicrobial resistance (AMR). The company focuses on creating therapies that address bacterial infections through novel modes of action and targets. BioVersys operates in the pharmaceutical and biotech sectors, serving healthcare systems globally by providing solutions to combat the silent pandemic of AMR. The business model revolves around advancing clinical trials and bringing effective treatments to market, thereby generating revenue through the commercialization of its pharmaceutical products. The company is governed by a board of directors with extensive experience in the pharma and biotech industries, ensuring strategic oversight and guidance. BioVersys is committed to improving patient outcomes and safeguarding global health by addressing one of the most pressing medical threats of our time. Keywords: antimicrobial resistance, small molecules, bacterial infections, pharmaceutical, biotech, clinical trials, healthcare, global health, therapies, Basel
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Basel, Switzerland
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 92.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Molecular, Spinout, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Nov 2025 | $16M | — | Undisclosed | ↗ |
| IPOOther financing | Feb 2025 | $73M | $195M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for BioVersys is 4.1K monthly website visits, up 7.9% over the last three months. BioVersys's team grew 28.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
EVA Basel
CARB-X
Series A1 investor entered at this stage
Business Angels Switzerland
Series B and later4 investors entered at this stage
European Investment Bank
AMR Action Fund
GSK
Guangzhou Industrial Investment Fund
Other known investors4 additional known investors
ETH Zurich
Mick Mende
Venture Kick
VentureLab
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioVersys on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioVersys’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.